Mega Contracts Monitor ($100M+) — February 03, 2026

Repeat wins totaling $457M fully obligated for GSA LPOE and NIH lab expansion signal market leadership in federal institutional builds through 2028.

$849M across 4 awards (R&D, data coordination, CMS support, lab expansion) with 47% outlayed reflects multi-year commitment amid infectious disease focus.

$304M BIOMAP award to nonprofit ATI shows stable but low-margin health manufacturing support with minimal outlay to date.

Low initial outlays ($33M avg. across contracts) signal potential slow ramps or delays in $1.13B portfolio.

Firm fixed-price (3 contracts, $735M) exposes to cost overruns in construction/infra amid inflation.

Long tenors to 2028 vulnerable to HHS/GSA budget shifts or audits on cost-plus structures ($673M).

$192M unexercised options across 3 contracts could boost values 15-70%.

NIH/NIAID lab expansions and infectious disease data centers position winners for follow-ons in $286M+ ceiling contracts.

75% of value ($849M) in HHS awards for labs, R&D manufacturing, CMS IT, and data coordination emphasizes post-pandemic resilience investments.

41% ($457M) in firm-fixed builds for labs/border facilities shows GSA/NIH prioritizing capacity expansions.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"$457M dual wins represent 41% of period value with $144M outlayed.", "trigger"=>"Outlay acceleration >20% QoQ or new GSA/NIH awards"}

{"entity"=>"HHS Budget Allocations", "reason"=>"Dominates 75% of value with extensions to 2028.", "trigger"=>"FY2027 appropriations cuts or infectious disease funding boosts"}

{"entity"=>"THE EMMES COMPANY", "reason"=>"$117M options upside in NIAID data center amid long-term infectious disease focus.", "trigger"=>"Option exercises lifting value to $287M"}